{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:59:53Z","timestamp":1792364393484,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Financial toxicity, defined as hardship from medical costs, is an emerging concept in healthcare. Here we define financial toxicity in head and neck cancer patients receiving radiation, identify risk factors, and determine associations with HRQoL, treatment morbidity, and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective study on consecutive patients referred to a tertiary referral center for radiation therapy for head and neck malignancies (July 2021\u2013June 2023). Patients provided consent and were assessed using validated patient-reported outcome measures for financial toxicity (FACIT-COST), HRQoL (EORTC-QLQ-C30), and symptom burden (PRO-CTCAE) before and after radiation therapy. Primary outcomes included two-year overall survival (OS), treatment morbidity (ER visits, hospitalizations, feeding tube placement, missed radiation days), HRQoL, and symptom burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 74 patients (median age 69), all completed pre-radiation therapy (pre-RT) measures, and 39 completed post-RT measures. Median pre-RT COST was 29 (range: 0\u201344), with 41.9% scoring \u226425, indicating worse financial toxicity. Lower pre-RT COST scores correlated with younger age, Black race, Medicaid insurance, single or unemployed status, advanced T-stage, and concurrent chemoradiotherapy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). These patients had worse HRQoL, more severe symptoms, increased feeding tube placements, and more ER visits\/hospitalizations (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). OS was worse with lower pre- (HR\u2009=\u20090.95; 95% CI\u2009=\u20090.91\u20130.99;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.015) and post-RT COST scores (HR\u2009=\u20090.92; 95% CI\u2009=\u20090.86\u20130.98;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Financial toxicity is common in head and neck radiation patients and linked to worse HRQoL, morbidity, and OS. Affected patients had clear socioeconomic risk factors and advanced disease. Further research should explore interventions to improve cancer outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-025-02749-x","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:46:27Z","timestamp":1764074787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Financial toxicity on treatment outcomes in head &amp; neck cancer patients undergoing radiation therapy"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7024-3783","authenticated-orcid":false,"given":"Garrett K.","family":"Harada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jino","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akul","family":"Munjal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupali","family":"Banker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Attarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelareh","family":"Sadigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"2749_CR1","unstructured":"National Cancer institute. Cancer stat facts: laryngeal Cancer. Surveillance, epidemiology, and end results program. n.d. https:\/\/seer.cancer.gov\/statfacts\/html\/laryn.html. accessed September 7, 2024."},{"key":"2749_CR2","unstructured":"National Cancer Institute. Cancer stat facts: oral cavity and Pharynx. Surveillance, epidemiology, and end results program. n.d. https:\/\/seer.cancer.gov\/statfacts\/html\/oralcav.html. accessed September 7, 2024."},{"key":"2749_CR3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1177\/10499091231187999","volume":"41","author":"JP Harris","year":"2024","unstructured":"Harris JP, Ku E, Harada G, Hsu S, Chiao E, Rao P, et al. Severity of financial toxicity for patients receiving palliative radiation therapy. Am J Hosp Palliat Care. 2024;41:592\u2013600. https:\/\/doi.org\/10.1177\/10499091231187999.","journal-title":"Am J Hosp Palliat Care"},{"key":"2749_CR4","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.3390\/curroncol29040202","volume":"29","author":"CJ Longo","year":"2022","unstructured":"Longo CJ. Linking intermediate to final \u201creal-world\u201d outcomes: is financial toxicity a reliable predictor of poorer outcomes in cancer? Curr Oncol. 2022;29:2483\u201389. https:\/\/doi.org\/10.3390\/curroncol29040202.","journal-title":"Curr Oncol"},{"key":"2749_CR5","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1016\/j.joms.2017.05.008","volume":"75","author":"M Mourad","year":"2017","unstructured":"Mourad M, Jetmore T, Jategaonkar AA, Moubayed S, Moshier E, Urken ML. Epidemiological trends of head and neck cancer in the United States: a seer population study. J Oral Maxillofac Surg. 2017;75:2562\u201372. https:\/\/doi.org\/10.1016\/j.joms.2017.05.008.","journal-title":"J Oral Maxillofac Surg"},{"key":"2749_CR6","doi-asserted-by":"publisher","first-page":"105196","DOI":"10.1016\/j.oraloncology.2021.105196","volume":"115","author":"SJ Ma","year":"2021","unstructured":"Ma SJ, Iovoli AJ, Attwood K, Wooten KE, Arshad H, Gupta V, et al. Association of significant financial burden with survival for head and neck cancer patients treated with radiation therapy. Oral Oncol. 2021;115:105196. https:\/\/doi.org\/10.1016\/j.oraloncology.2021.105196.","journal-title":"Oral Oncol"},{"key":"2749_CR7","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-19-1534","volume":"29","author":"AB Mariotto","year":"2020","unstructured":"Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarker Prev. 2020;29:1304\u201312. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-1534.","journal-title":"Cancer Epidemiol Biomarker Prev"},{"key":"2749_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9:465\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7826.","journal-title":"JAMA Oncol"},{"key":"2749_CR9","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1200\/OP.21.00440","volume":"18","author":"J Panzone","year":"2022","unstructured":"Panzone J, Welch C, Morgans A, Bhanvadia SK, Mossanen M, Shenhav-Goldberg R, et al. Association of race with cancer-related financial toxicity. JCO Oncol Pract. 2022;18:e271\u201383. https:\/\/doi.org\/10.1200\/OP.21.00440.","journal-title":"JCO Oncol Pract"},{"key":"2749_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cncr.30369","volume":"123","author":"de Souza Ja","year":"2017","unstructured":"de Souza Ja, Yap BJ, Wroblewski K, Blinder V, Ara\u00fajo FS, Hlubocky FJ, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive score for financial toxicity (COST). Cancer. 2017;123:476\u201384. https:\/\/doi.org\/10.1002\/cncr.30369.","journal-title":"Cancer"},{"key":"2749_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s11136-013-0520-8","volume":"23","author":"JD Peipert","year":"2014","unstructured":"Peipert JD, Beaumont JL, Bode R, Cella D, Garcia SF, Hahn EA. Development and validation of the functional assessment of chronic illness therapy treatment satisfaction (facit ts) measures. Qual Life Res. 2014;23:815\u201324. https:\/\/doi.org\/10.1007\/s11136-013-0520-8.","journal-title":"Qual Life Res"},{"key":"2749_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","volume":"178","author":"K Cocks","year":"2023","unstructured":"Cocks K, Wells JR, Johnson C, Schmidt H, Koller M, Oerlemans S, et al. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. Eur J Cancer. 2023;178:128\u201338. https:\/\/doi.org\/10.1016\/j.ejca.2022.10.026.","journal-title":"Eur J Cancer"},{"key":"2749_CR13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, et al. Validity and reliability of the us National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. 2015;1:1051\u201359. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2639.","journal-title":"JAMA Oncol"},{"key":"2749_CR14","unstructured":"Census Bureau Data. n.d. https:\/\/data.census.gov\/. accessed May 7, 2024."},{"key":"2749_CR15","unstructured":"FACIT-TS-G. FACIT Group. n.d. https:\/\/www.facit.org\/measures\/facit-ts-g. accessed September 7, 2024."},{"key":"2749_CR16","unstructured":"FACIT-COST. FACIT Group. n.d. https:\/\/www.facit.org\/measures\/facit-cost. accessed September 7, 2024."},{"key":"2749_CR17","unstructured":"Quality of life group. EORTC QLQ-C30. EORTC \u2013 quality of life 2017. https:\/\/qol.eortc.org\/questionnaires\/core\/eortc-qlq-c30\/. accessed September 7, 2024."},{"key":"2749_CR18","unstructured":"Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). n.d. https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/. accessed September 7, 2024."},{"key":"2749_CR19","doi-asserted-by":"publisher","unstructured":"De Souza JA, Wroblewski K, Proussaloglou E, Nicholson L, Hantel A, Wang Y. Validation of a financial toxicity (ft) grading system. JCO. 2017;35:6615\u20136615. https:\/\/doi.org\/10.1200\/.JCO.2017.35.15_suppl.6615.","DOI":"10.1200\/.JCO.2017.35.15_suppl.6615"},{"key":"2749_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/jco.2016.34.3_suppl.16","volume":"34","author":"JA De Souza","year":"2016","unstructured":"De Souza JA, Aschebrook-Kilfoy B, Grogan R, Yap BJ, Daugherty C, Cella D. Grading financial toxicity based upon its impact on health-related quality of life (HRQol). JCO. 2016;34:16\u201316. https:\/\/doi.org\/10.1200\/jco.2016.34.3_suppl.16.","journal-title":"JCO"},{"key":"2749_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s00520-023-07849-6","volume":"31","author":"KM Esselen","year":"2023","unstructured":"Esselen KM, Baig RA, Gompers A, Stack-Dunnbier H, Hacker MR, Jang JW. Factors associated with increased financial toxicity after the completion of radiation treatment for gynecologic cancer. Support Care Cancer. 2023;31:388. https:\/\/doi.org\/10.1007\/s00520-023-07849-6.","journal-title":"Support Care Cancer"},{"key":"2749_CR22","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1002\/cncr.28814","volume":"120","author":"de Souza Ja","year":"2014","unstructured":"de Souza Ja, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 2014;120:3245\u201353. https:\/\/doi.org\/10.1002\/cncr.28814.","journal-title":"Cancer"},{"key":"2749_CR23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.4143\/crt.2021.784","volume":"54","author":"S Shim","year":"2021","unstructured":"Shim S, Kang D, Kim N, Han G, Lim J, Kim H, et al. Validation of Korean version of the COmprehensive score for financial toxicity (COST) among breast cancer survivors. Cancer Res Treat. 2021;54:834\u201341. https:\/\/doi.org\/10.4143\/crt.2021.784.","journal-title":"Cancer Res Treat"},{"key":"2749_CR24","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1016\/j.prro.2021.11.003","volume":"12","author":"M Yusuf","year":"2022","unstructured":"Yusuf M, Pan J, Rai SN, Eldredge-Hindy H. Financial toxicity in women with breast cancer receiving radiation therapy: final results of a prospective observational study. Pract Radiat Oncol. 2022;12:e79\u201389. https:\/\/doi.org\/10.1016\/j.prro.2021.11.003.","journal-title":"Pract Radiat Oncol"},{"key":"2749_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14639\/0392-100X-N2762","volume":"44","author":"E Raggini","year":"2024","unstructured":"Raggini E, Mattavelli D, Zigliani G, Bossi P, Piazza C. Measuring financial toxicity in head and neck cancer: a systematic review. Acta Otorhinolaryngol Ital. 2024;44:1\u201312. https:\/\/doi.org\/10.14639\/0392-100X-N2762.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"2749_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1200\/JCO.2015.62.0468","volume":"34","author":"KR Yabroff","year":"2016","unstructured":"Yabroff KR, Dowling EC, Guy GP, Banegas MP, Davidoff A, Han X, et al. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol. 2016;34:259\u201367. https:\/\/doi.org\/10.1200\/JCO.2015.62.0468.","journal-title":"J Clin Oncol"},{"key":"2749_CR27","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1377\/hlthaff.2012.1263","volume":"32","author":"S Ramsey","year":"2013","unstructured":"Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (millwood). 2013;32:1143\u201352. https:\/\/doi.org\/10.1377\/hlthaff.2012.1263.","journal-title":"Health Aff (millwood)"},{"key":"2749_CR28","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.6004\/jnccn.2017.0161","volume":"15","author":"CR Meeker","year":"2017","unstructured":"Meeker CR, Wong Y-N, Egleston BL, Hall MJ, Plimack ER, Martin LP, et al. Distress and financial distress in adults with cancer: an age-based analysis. J Natl Compr Canc Netw. 2017;15:1224\u201333. https:\/\/doi.org\/10.6004\/jnccn.2017.0161.","journal-title":"J Natl Compr Canc Netw"},{"key":"2749_CR29","doi-asserted-by":"publisher","first-page":"e2350844","DOI":"10.1001\/jamanetworkopen.2023.50844","volume":"7","author":"S Kircher","year":"2024","unstructured":"Kircher S, Duan F, An N, Gareen IF, Sicks JD, Sadigh G, et al. Patient-reported financial burden of treatment for colon or rectal cancer. JAMA Netw Open Open. 2024;7:e2350844. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50844.","journal-title":"JAMA Netw Open Open"},{"key":"2749_CR30","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/annonc\/mdw433","volume":"27","author":"F Perrone","year":"2016","unstructured":"Perrone F, Jommi C, Di Maio M, Gimigliano A, Gridelli C, Pignata S, et al. The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. Ann Oncol. 2016;27:2224\u201329. https:\/\/doi.org\/10.1093\/annonc\/mdw433.","journal-title":"Ann Oncol"},{"key":"2749_CR31","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2217\/fon-2018-0874","volume":"15","author":"J Klein","year":"2019","unstructured":"Klein J, Bodner W, Garg M, Kalnicki S, Ohri N. Pretreatment financial toxicity predicts progression-free survival following concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer. Future Oncol. 2019;15:1697\u2013705. https:\/\/doi.org\/10.2217\/fon-2018-0874.","journal-title":"Future Oncol"},{"key":"2749_CR32","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","volume":"34","author":"SD Ramsey","year":"2016","unstructured":"Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34:980\u201386. https:\/\/doi.org\/10.1200\/JCO.2015.64.6620.","journal-title":"J Clin Oncol"},{"key":"2749_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ygyno.2021.01.040","volume":"161","author":"KM Esselen","year":"2021","unstructured":"Esselen KM, Stack-Dunnbier H, Gompers A, Hacker MR. Crowdsourcing to measure financial toxicity in gynecologic oncology. Gynecologic Oncol. 2021;161:595\u2013600. https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.040.","journal-title":"Gynecologic Oncol"},{"key":"2749_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ygyno.2019.04.003","volume":"154","author":"S Bouberhan","year":"2019","unstructured":"Bouberhan S, Shea M, Kennedy A, Erlinger A, Stack-Dunnbier H, Buss MK, et al. Financial toxicity in gynecologic oncology. Gynecologic Oncol. 2019;154:8\u201312. https:\/\/doi.org\/10.1016\/j.ygyno.2019.04.003.","journal-title":"Gynecologic Oncol"},{"key":"2749_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00520-021-06424-1","volume":"30","author":"G Sadigh","year":"2022","unstructured":"Sadigh G, Switchenko J, Weaver KE, Elchoufi D, Meisel J, Bilen MA, et al. Correlates of financial toxicity in adult cancer patients and their informal caregivers. Support Care Cancer. 2022;30:217\u201325. https:\/\/doi.org\/10.1007\/s00520-021-06424-1.","journal-title":"Support Care Cancer"},{"key":"2749_CR36","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cncr.30369","volume":"123","author":"de Souza Ja","year":"2017","unstructured":"de Souza Ja, Yap BJ, Wroblewski K, Blinder V, Ara\u00fajo FS, Hlubocky FJ, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the Comprehensive score for financial toxicity (COST). Cancer. 2017;123:476\u201384. https:\/\/doi.org\/10.1002\/cncr.30369.","journal-title":"Cancer"},{"key":"2749_CR37","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1007\/s00520-019-05286-y","volume":"28","author":"CI Ripamonti","year":"2020","unstructured":"Ripamonti CI, Chiesi F, Di Pede P, Guglielmo M, Toffolatti L, Gangeri L, et al. The validation of the Italian version of the comprehensive score for financial toxicity (COST). Support Care Cancer. 2020;28:4477\u201385. https:\/\/doi.org\/10.1007\/s00520-019-05286-y.","journal-title":"Support Care Cancer"},{"key":"2749_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/07347332.2020.1836547","volume":"39","author":"B Thom","year":"2021","unstructured":"Thom B, Mamoor M, Lavery JA, Baxi SS, Khan N, Rogak LJ, et al. The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. J Psychosoc Oncol. 2021;39:285\u201393. https:\/\/doi.org\/10.1080\/07347332.2020.1836547.","journal-title":"J Psychosoc Oncol"},{"key":"2749_CR39","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2022.07.017","volume":"26","author":"S Pangestu","year":"2023","unstructured":"Pangestu S, Rencz F. Comprehensive score for financial toxicity and health-related quality of life in patients with cancer and survivors: a systematic review and meta-analysis. Value Health. 2023;26:300\u201316. https:\/\/doi.org\/10.1016\/j.jval.2022.07.017.","journal-title":"Value Health"},{"key":"2749_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","volume":"18","author":"SY Zafar","year":"2013","unstructured":"Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer Patient\u2019s experience. Oncologist. 2013;18:381\u201390. https:\/\/doi.org\/10.1634\/theoncologist.2012-0279.","journal-title":"Oncologist"},{"key":"2749_CR41","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3390\/ijerph16081343","volume":"16","author":"K Lamore","year":"2019","unstructured":"Lamore K, Dubois T, Rothe U, Leonardi M, Girard I, Manuwald U, et al. Return to work interventions for cancer survivors: a systematic review and a methodological critique. Int J Environ Res Public Health. 2019;16:1343. https:\/\/doi.org\/10.3390\/ijerph16081343.","journal-title":"Int J Environ Res Public Health"},{"key":"2749_CR42","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.37765\/ajmc.2022.89151","volume":"28","author":"KD Parekh","year":"2022","unstructured":"Parekh KD, Wong WB, Zullig LL. Impact of co-pay assistance on patient, clinical, and economic outcomes. Am J Manag Care. 2022;28:e189\u201397. https:\/\/doi.org\/10.37765\/ajmc.2022.89151.","journal-title":"Am J Manag Care"},{"key":"2749_CR43","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1016\/j.cllc.2019.02.010","volume":"20","author":"KR Voong","year":"2019","unstructured":"Voong KR, Liang OS, Dugan P, Torto D, Padula WV, Senter JP, et al. Thoracic oncology multidisciplinary clinic reduces unnecessary health care expenditure used in the workup of patients with non-small-cell lung cancer. Clin Lung Cancer. 2019;20:e430\u201341. https:\/\/doi.org\/10.1016\/j.cllc.2019.02.010.","journal-title":"Clin Lung Cancer"},{"key":"2749_CR44","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1257\/aeri.20210515","volume":"4","author":"A Adams","year":"2022","unstructured":"Adams A, Kluender R, Mahoney N, Wang J, Wong F, Yin W. The Impact of financial assistance programs on health care utilization: evidence from Kaiser Permanente. Am Econ Rev Insights. 2022;4:389\u2013407. https:\/\/doi.org\/10.1257\/aeri.20210515.","journal-title":"Am Econ Rev Insights"},{"key":"2749_CR45","doi-asserted-by":"publisher","unstructured":"Khan G, Karabon P, Lerchenfeldt S. Use of prescription assistance programs after the affordable health care act. J Manag Care Spec Pharm. 2018;24. https:\/\/doi.org\/10.18553\/jmcp.2018.24.3.247. 10.18553\/jmcp.2018.24.3.247.","DOI":"10.18553\/jmcp.2018.24.3.247"},{"key":"2749_CR46","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1002\/cncr.35367","volume":"130","author":"A Rashidi","year":"2024","unstructured":"Rashidi A, Jung J, Kao R, Nguyen EL, Le T, Ton B, et al. Interventions to mitigate cancer-related medical financial hardship: a systematic review and meta-analysis. Cancer. 2024;130:3198\u2013209. https:\/\/doi.org\/10.1002\/cncr.35367.","journal-title":"Cancer"},{"key":"2749_CR47","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.jacr.2024.04.024","volume":"21","author":"NL Samaha","year":"2024","unstructured":"Samaha NL, Mady LJ, Armache M, Hearn M, Stemme R, Jagsi R, et al. Screening for financial toxicity among patients with cancer: a systematic review. J Am Coll Radiol. 2024;21:1380\u201397. https:\/\/doi.org\/10.1016\/j.jacr.2024.04.024.","journal-title":"J Am Coll Radiol"},{"key":"2749_CR48","doi-asserted-by":"publisher","first-page":"825","DOI":"10.6004\/jnccn.2020.7538","volume":"18","author":"N Khera","year":"2020","unstructured":"Khera N, Sugalski J, Krause D, Butterfield R, Zhang N, Stewart FM, et al. Current practices for screening and management of financial distress at NCCN member institutions. J Natl Compr Canc Netw. 2020;18:825\u201331. https:\/\/doi.org\/10.6004\/jnccn.2020.7538.","journal-title":"J Natl Compr Canc Netw"},{"key":"2749_CR49","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jacr.2023.12.025","volume":"21","author":"R Bansal","year":"2024","unstructured":"Bansal R, Anderson D, Cuyegkeng A, Tran T-N, Aijaz A, Dhillon J, et al. Feasibility of screening for financial hardship and health-related social needs at radiology encounters. J Am Coll Radiol. 2024;21:1362\u201370. https:\/\/doi.org\/10.1016\/j.jacr.2023.12.025.","journal-title":"J Am Coll Radiol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02749-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02749-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02749-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:46:32Z","timestamp":1764074792000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02749-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2749"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02749-x","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Ethical approval was obtained and all procedures in this study were conducted in accordance with the University of California, Irvine - Institutional Review Board #2639 approved protocols.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Written informed consent was obtained from the patients for their anonymized information to be published in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}